红日药业：10月27日召开董事会会议

Company Overview - Hongri Pharmaceutical (SZ 300026) announced its third board meeting of the ninth session held on October 27, 2025, in Tianjin, where the agenda included the discussion of the 2025 Q3 report [1] - As of the report, Hongri Pharmaceutical has a market capitalization of 11.4 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of Hongri Pharmaceutical is as follows: - Traditional Chinese medicine formula granules and decoction pieces account for 46.15% - Finished drugs account for 24.72% - Medical devices account for 19.39% - Auxiliary materials and raw materials account for 8.33% - Other industries account for 1.42% [1]